As of Nov 19, 2026, 2 of 2 active firms rate BTAI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BTAI EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 0 analysts
Next period, 0 analysts expect BioXcel Therapeutics Inc to earn — a share (range — – —), versus — a year earlier. , growing to $-2.14 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 0 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $20.8M next year.
Top analysts covering BioXcel Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BTAI.
#1
Graig Suvannavejh
Mizuho · Rank #239
Neutral
$4.00+8250.7% to target
Overall win rate
40%
+ Follow
#2
Sumant Kulkarni
Canaccord Genuity · Rank #419
Buy
$18.00+37478.3% to target
Overall win rate
39%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$5.00+10338.4% to target
Overall win rate
36%
+ Follow
#4
MK
Michael King
Rodman & Renshaw
Buy
$17.00+35390.6% to target
Coverage
—
+ Follow
#5
Elemer Piros
Lucid Capital
Buy
No targeton BTAI
Coverage
—
+ Follow
BTAI stock forecast FAQ
What is BTAI's average 12-month price target?+
The 2 active firms with a live target average $11.00 for BioXcel Therapeutics Inc over the next 12 months, ranging from a $17.00 high to a $5.00 low, as of Nov 19, 2026.
Is BTAI stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BTAI?+
The Street-high target is $17.00 (Rodman & Renshaw), and the Street-low is $5.00 (HC Wainwright & Co.). The average of all 2 active-firm targets is $11.00.
How many active Wall Street firms cover BTAI?+
2 active firms have a recognized rating on BioXcel Therapeutics Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BTAI?+
Among analysts who currently cover BTAI, Graig Suvannavejh of Mizuho has the strongest overall Quantellect track record (Rank #239). Their current call is Neutral with a $4.00 target.
What is BioXcel Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 0 analysts. Full-year EPS is projected at —, rising to $-2.14 the following year.
How much revenue is BioXcel Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $20.8M next year.
Have analysts been upgrading or downgrading BTAI lately?+
As of Nov 19, 2026, 2 of 2 active firms rate BTAI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BTAI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.